In this issue:
Evaluation of DFS as an intermediate metric of OS in localised RCC
SABR for primary RCC
Phase 1 trial of PT2385 in patients with previously treated advanced ccRCCs
Axitinib + pembrolizumab in patients with advanced RCC
Patients’ preferences for adjuvant sorafenib after resection of RCC
Impact of LND on cancer-specific mortality in non-metastatic RCC treated with radical nephrectomy
The role of LND in the management of RCC
Survival following initial cytoreductive nephrectomy vs initial targeted therapy for mRCC
Tumour size cut-points for RCC
Observation after CN in patients with synchronous not completely resected metastases of RCC
Updated European Association of Urology guidelines: Recommendations for the treatment of first-line metastatic clear cell renal cancer
Please login below to download this issue (PDF)